The Significance of FIGO Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma.

[1]  M. Ladanyi,et al.  Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile , 2022, Modern Pathology.

[2]  T. Bosse,et al.  Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. , 2022, Gynecologic oncology.

[3]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[4]  Gloria S. Huang,et al.  A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability , 2021, Cancer.

[5]  A. Talhouk,et al.  Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis , 2021, Cancer.

[6]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Pasanen,et al.  Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma , 2020, Modern Pathology.

[8]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Liliana Villafania,et al.  Reliable Clinical MLH1 Promoter Hypermethylation Assessment using a High-Throughput Genome-Wide Methylation Array Platform. , 2019, The Journal of molecular diagnostics : JMD.

[10]  C. Gilks,et al.  Interpretation of somatic POLE mutations in endometrial carcinoma , 2019, The Journal of pathology.

[11]  C. Gilks,et al.  Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.

[12]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Nadeem Riaz,et al.  Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. , 2019, Gynecologic oncology.

[14]  C. Gilks,et al.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.

[15]  G. Getz,et al.  Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair , 2018, Nature Communications.

[16]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  N. de Wind,et al.  Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues , 2018, Clinical Cancer Research.

[18]  Kathleen R. Cho,et al.  Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  Wei Chen,et al.  Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. , 2017, Gynecologic oncology.

[20]  A. Ayhan,et al.  Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus , 2017, Journal of gynecologic oncology.

[21]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[22]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[23]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[24]  H. Morreau,et al.  Practical guidance for mismatch repair-deficiency testing in endometrial cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Yoshikawa,et al.  Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. , 2016, Gynecologic oncology.

[26]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[27]  A. Talhouk,et al.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.

[28]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[29]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[30]  M. Leitao,et al.  Grading Uterine Endometrioid Carcinoma: A Proposal That Binary Is Best , 2014, The American journal of surgical pathology.

[31]  M. Köbel,et al.  POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. , 2014, Gynecologic oncology.

[32]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[33]  R. Barakat,et al.  Redefining Stage I Endometrial Cancer: Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment , 2013, International Journal of Gynecologic Cancer.

[34]  Alexia Iasonos,et al.  Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. , 2013, Gynecologic oncology.

[35]  C Blake Gilks,et al.  Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.

[36]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[37]  I. Tomlinson,et al.  DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer , 2013, Human molecular genetics.

[38]  G. Tulunay,et al.  Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters , 2007, International Journal of Gynecologic Cancer.

[39]  M. Jacobsen,et al.  Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[40]  A. L. Nielsen,et al.  Evaluation of the reproducibility of the revised 1988 international federation of gynecology and obstetrics grading system of endometrial cancers with special emphasis on nuclear grading , 1991, Cancer.

[41]  R. Kurman,et al.  The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study , 1995, Cancer.

[42]  C. Kosary.  FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. , 1994, Seminars in surgical oncology.